ARHGAP17: A Potential Drug Target for Neurological and Cardiovascular Disorders

Target Name: ARHGAP17

NCBI ID: G55114

ARHGAP17

ARHGAP17: A Potential Drug Target for Neurological and Cardiovascular Disorders

ARHGAP17 (also known as MST066) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a part of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

ARHGAP17 is a 21-kDa protein that is expressed in the brain, heart, and lungs, and is highly conserved across species. It is localized to the dendrites of neurons and endothelial cells, and is involved in the regulation of various cellular processes, including cell signaling, neurotransmitter release, and inflammation.

One of the most promising aspects of ARHGAP17 is its potential as a drug target. The GPCR family is known for their ability to be targeted by small molecules, which makes them an attractive target for drug development. Additionally, the role of ARHGAP17 in various cellular processes makes it an attractive target for the treatment of various neurological and cardiovascular disorders.

ARHGAP17 has been shown to play a role in neurotransmitter release and cell signaling. It is a critical regulator of neurotransmitter release from neurons, and has been shown to play a role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Additionally, ARHGAP17 has also been shown to play a role in the regulation of inflammation. It is a critical regulator of the chemokine receptor, which is a protein that is involved in the regulation of immune responses. ARHGAP17 has been shown to play a role in the regulation of chemokine receptor function, and has been shown to play a role in the regulation of immune cell function.

The potential drug targets for ARHGAP17 are vast, and include the treatment of various neurological and cardiovascular disorders. For example, ARHGAP17 has been shown to be involved in the regulation of neurotransmitter release, which makes it an attractive target for the treatment of disorders such as depression, anxiety, and PTSD. Additionally, ARHGAP17 has also been shown to play a role in the regulation of inflammation, which makes it an attractive target for the treatment of autoimmune disorders such as rheumatoid arthritis and lupus.

In conclusion, ARHGAP17 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of various cellular processes, including cell signaling, neurotransmitter release, and inflammation. Its potential as a drug target makes it an attractive target for the development of new treatments for a variety of neurological and cardiovascular disorders. Further research is needed to fully understand the role of ARHGAP17 in cellular signaling and its potential as a drug target.

Protein Name: Rho GTPase Activating Protein 17

Functions: Rho GTPase-activating protein involved in the maintenance of tight junction by regulating the activity of CDC42, thereby playing a central role in apical polarity of epithelial cells. Specifically acts as a GTPase activator for the CDC42 GTPase by converting it to an inactive GDP-bound state. The complex formed with AMOT acts by regulating the uptake of polarity proteins at tight junctions, possibly by deciding whether tight junction transmembrane proteins are recycled back to the plasma membrane or sent elsewhere. Participates in the Ca(2+)-dependent regulation of exocytosis, possibly by catalyzing GTPase activity of Rho family proteins and by inducing the reorganization of the cortical actin filaments. Acts as a GTPase activator in vitro for RAC1

The "ARHGAP17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets